# Dovitinib in Neuroendocrine Tumors

> **NCT01635907** · PHASE2 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 8 (actual)

## Conditions studied

- Advanced Metastatic Paraganglioma
- Advanced Metastatic Pheochromocytoma
- Recurrent Paraganglioma
- Recurrent Pheochromocytoma
- Unresectable Paraganglioma
- Unresectable Pheochromocytoma

## Interventions

- **DRUG:** Dovitinib

## Key facts

- **NCT ID:** NCT01635907
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2016-03
- **Final completion:** 2016-04-11
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2020-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01635907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01635907, "Dovitinib in Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01635907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*